Insight on Pharmaceuticals

The following industries match your search criteria:

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

Results are sorted by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

Pharmaceutical Licensing and Alliances in the Asia-Pacific Region – Pharma enhances its focus on APAC markets

An overview of licensing and alliance trends in developed and emerging pharmaceutical markets in the Asia-Pacific region from Q3 2009 to Q2 2010, including discussion of the drivers of recent deals and analysis of key agreements.

Published By Datamonitor
19 Nov 2010 $2800
Buy
Case Studies
Case Studies

Transition at Teva: Blockbuster drug Copaxone to lose patent protection in 2014

This case study looks at Teva's operations and the market in which it operates, Copaxone, Teva's best-selling drug, and M&A activity Teva has been involved in over recent years, and whether or not it has been successful.

Published By MarketLine
11 Apr 2014 $495
Buy
Case Studies
Case Studies

Orphan Drugs: Rescue from the patent cliff

Big Pharma has gone through some significant changes in recent years: many “blockbuster” drugs are losing their patents. In the orphan drugs market, where companies can charge high premiums for drugs which have little to no competition.

Published By MarketLine
03 Dec 2013 $495
Buy
Case Studies
Case Studies

Pfizer Inc: Re-entry to the OTC healthcare market

Pfizer exited the OTC healthcare market in 2006 with the sale of its Consumer Healthcare division. In 2009, Pfizer re-entered the market. This case study will examine Pfizer's growth, disposal of the OTC division, and the subsequent market re-entry.

Published By MarketLine
11 Apr 2013 $495
Buy
Case Studies
Case Studies

Johnson & Johnson: Product recalls in the OTC pharmaceuticals business

Johnson & Johnson is the largest manufacturer of over-the-counter (OTC) healthcare products in the US. However, this position has been threatened in recent years by a number of manufacturing issues that have led to a series of product recalls.

Published By MarketLine
28 Jan 2013 $495
Buy
Case Studies
Case Studies

Alexion Pharmaceuticals, Inc.: Focus on ultra-rare diseases as a revenue and profit driver

In 2007, Alexion gained marketing approval for Soliris, which has since become the world’s single most expensive orphan drug. This case study analyzes Alexion's success with Soliris, potential challenges, and how it is combatting these going forward.

Published By MarketLine
16 Jan 2013 $495
Buy
Report
Report

Micro and Nano Technologies for Point-of-Care Testing

Micro and nanotechnologies are set to transform point-of-care diagnostics. Miniaturization of testing methods, advances in lab-on-a-chip microfluidic methodologies, improvements in detection technologies and novel biosensors are leading the way.

Published By Datamonitor
17 Oct 2012 $2800
Buy
Report
Report

Partnership Models and Emerging Destinations for R&D Outsourcing

This report reviews the different types of relationship models between contract research organizations (CROs) and sponsors, and forecasts the leading next-wave clinical trial destinations.

Published By Datamonitor
23 Aug 2012 $2800
Buy
Case Studies
Case Studies

The "Patent Cliff": How Pfizer has responded to the loss of its best-selling drug

The pharmaceuticals market is currently in the middle of a "patent cliff." This case study looks at the various routes companies are taking in order to minimize the adverse effects caused by the patent cliff.

Published By MarketLine
08 Jun 2012 $495
Buy
Report
Report

Apotex Inc.: PharmaVitae Report

Analysis of Apotex's corporate strategy, marketed portfolio and pipeline potential over 2010-2016.

Published By Datamonitor
21 Dec 2011 $2800
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

No help is available.